Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. on January 26, 2022. The filing primarily discloses the entry into a material definitive agreement to sell its T-Cell Operations and Manufacturing facility (the "ATOM Facility") and related assets to FUJIFILM Diosynth Biotechnologies California, Inc.
Key Financial Metrics and Transaction Details
- Transaction Value: FUJIFILM will pay approximately $100 million in cash at closing, subject to adjustments for inventory levels and potential delays.
- Asset Transfer: The sale includes all rights, title, and interest in the ATOM Facility located in Thousand Oaks, California.
- Liabilities Assumed: FUJIFILM will assume certain contracts and obligations, including future rent payments for the facility.
- Liquidity Estimate: The Company issued a preliminary, unaudited estimate of its cash, cash equivalents, and short-term investments as of December 31, 2021, in a press release furnished as Exhibit 99.1. The filing text does not provide the specific dollar amount of this estimate.
- Revenue and Profit: The filing does not provide specific revenue, profit, or margin figures for the period.
Material Changes and Agreements
The Company entered into three primary agreements effective upon the transaction closing:
- Asset Purchase Agreement: Governs the sale of the ATOM Facility. Closing is expected in the quarter ending June 30, 2022, subject to conditions including Hart-Scott-Rodino Act clearance.
- Master Services and Supply Agreement (MSA): A non-exclusive agreement allowing FUJIFILM to supply the Company with cell therapy products for up to 10 years post-closing.
- Transition Services Agreement: Atara will provide transition support services to FUJIFILM for up to 12 months following closing at FUJIFILM's expense.
Management Commentary, Risks, and Personnel Changes
- Executive Transition: Joseph Newell, Executive Vice President and Chief Operations Officer, will transition from employee to consultant effective January 31, 2022. He will receive a consulting fee of $10,000 monthly for the first year and $5,000 monthly for the second year, plus severance benefits including 12 months of base salary continuation and health care.
- Risks and Contingencies: The transaction is subject to closing conditions, including regulatory clearance. The estimated cash position as of December 31, 2021, is preliminary and unaudited, subject to change upon final audit.
- Forward-Looking Statements: The report contains forward-looking statements regarding the transaction timing and financial estimates, which are subject to risks and uncertainties.
Key Facts for Investor Verification
- Verify the final audited cash, cash equivalents, and short-term investment balance as of December 31, 2021, once the annual report is filed.
- Monitor the status of Hart-Scott-Rodino Antitrust Improvements Act clearance required for the transaction closing.
- Review the full text of the Asset Purchase Agreement and MSA when filed in the Form 10-Q for the period ended March 31, 2022, to understand specific covenants and termination rights.
- Confirm the exact closing date and any adjustments to the $100 million purchase price once the transaction is finalized.